Ligilactobacillus salivarius is a probiotic bacteria species that has been found to live in the gastrointestinal tract and exert a range of therapeutic properties including suppression of pathogenic bacteria.[1]
| Ligilactobacillus | |
|---|---|
| Scientific classification | |
| Domain: | |
| Phylum: | |
| Class: | |
| Order: | |
| Family: | |
| Genus: | |
| Binomial name | |
| Ligilactobacillus salivarius (Rogosa et al. 1953) Zheng et al. 2020
| |
| Synonyms | |
| |
Therapeutic research edit
Irritable bowel syndrome edit
Ligilactobacillus salivarius has been found to be of benefit in the alleviation of flatulence in individuals suffering from irritable bowel syndrome.[2]
Pancreatic necrosis edit
Pancreatic necrosis, if left untreated, has an almost 100 percent fatality rate due to bacterial translocation[further explanation needed]. Ligilactobacillus salivarius has been found to have a wide spectrum of coverage against pathogenic organisms that translocate from the gastrointestinal tract thereby demonstrating therapeutic benefit in the management of pancreatic necrosis. Research has shown that the addition of this species along with other probiotic species (specifically Bifidobacterium bifidum, Bifidobacterium infantis, Lactobacillus acidophilus, Lacticaseibacillus casei, and Lactococcus lactis) suppressed pro-inflammatory cytokines and further suppressed bacterial overgrowth in the small intestine leading to a reduction in bacterial translocation.[3]
Atopic dermatitis edit
Atopic dermatitis symptoms have been shown to be reversed in some children.[4]
References edit
- ^ Neville, BA.; O'Toole, PW. (May 2010). "Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species". Future Microbiol. 5 (5): 759–74. doi:10.2217/fmb.10.35. PMID 20441548.
- ^ Ortiz-Lucas, M.; Tobías, A.; Saz, P.; Sebastián, JJ. (Jan 2013). "Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis". Rev Esp Enferm Dig. 105 (1): 19–36. doi:10.4321/s1130-01082013000100005. PMID 23548007.
- ^ Ridwan, BU.; Koning, CJ.; Besselink, MG.; Timmerman, HM.; Brouwer, EC.; Verhoef, J.; Gooszen, HG.; Akkermans, LM. (Jan 2008). "Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis". Lett Appl Microbiol. 46 (1): 61–7. doi:10.1111/j.1472-765X.2007.02260.x. PMID 17944834.
- ^ Niccoli, A. A.; et al. (Nov–Dec 2014). "Preliminary Results on Clinical Effects of Probiotic Lactobacillius Salivarius LS01 in Children Affected by Atopic Dermatitis". Journal of Clinical Gastroenterology. 48 (48, supplement 1): S34–6. doi:10.1097/mcg.0000000000000233. PMID 25291124.